Stock Events

Stock Events

Astria Therapeutics 

$12.13
0
+$0+0% Monday 06:34

Statistics

Day High
12.13
Day Low
12.13
52W High
-
52W Low
-
Volume
108
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5MarExpected
Q3 2025
Q4 2025
-0.55
-0.5
-0.44
-0.39
Expected EPS
-0.46
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-188.52MNet Income

Analyst Ratings

$13.00Average Price Target
The highest estimate is 13.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATXS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biotech space with Astria Therapeutics' focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the development of therapies for serious medical conditions, potentially overlapping with Astria's target markets.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases and rare disease markets, directly competing with Astria Therapeutics' interest areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, aligning closely with Astria's focus.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is known for its work on genetic modulation therapies, including treatments for rare diseases, making it a direct competitor.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, competing in the same niche as Astria.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing, a cutting-edge area that could overlap with Astria Therapeutics' focus on innovative treatments for rare diseases.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its advanced gene therapy and innovative healthcare solutions, competes across a broad range of therapeutic areas including rare diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer operates in various therapeutic areas, including rare diseases, through its internal development and strategic acquisitions, making it a competitor.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, with its focus on antiviral drugs and other therapeutic areas, has the potential to compete in the rare disease market space targeted by Astria.

About

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Show more...
CEO
ISIN
US04635X1028

Listings

XNAS
US
ATXS
BOATS
BOATS
ATXS.BOATS

0 Comments

Share your thoughts

FAQ

What is Astria Therapeutics stock price today?▼
The current price of ATXS.BOATS is $12.13 USD — it has increased by +0% in the past 24 hours. Watch Astria Therapeutics stock price performance more closely on the chart.
What is Astria Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Astria Therapeutics stocks are traded under the ticker ATXS.BOATS.
What is Astria Therapeutics revenue for the last year?▼
Astria Therapeutics revenue for the last year amounts to 0 USD.
What is Astria Therapeutics net income for the last year?▼
ATXS.BOATS net income for the last year is -188.52M USD.
When did Astria Therapeutics complete a stock split?▼
Astria Therapeutics has not had any recent stock splits.